last
decad
varieti
molecular
assay
target
respiratori
virus
develop
commerci
therefor
multiplex
pcr
increasingli
use
everyday
clinic
practic
improv
understand
respiratori
viru
epidemiolog
enhanc
concern
clinic
impact
specif
patient
popul
howev
question
remain
regard
costeffect
perform
diagnost
test
routin
real
impact
patient
care
articl
review
avail
data
highlight
unresolv
question
costeffect
infect
control
clinic
util
public
health
impact
multiplex
respiratori
viru
assay
respiratori
virus
rv
ubiquit
caus
larg
varieti
clinic
symptom
mani
year
procedur
diagnosi
respiratori
viru
infect
includ
cultur
serolog
time
consum
labor
intens
insensit
direct
immunofluoresc
assay
dfa
improv
turnaround
time
slightli
compromis
sensit
compar
cultur
recent
molecular
assay
develop
progress
multiplex
order
diagnos
larg
number
respiratori
virus
singl
assay
new
virus
could
detect
convent
virolog
discov
variou
commerci
multiplex
respiratori
viru
assay
access
mani
clinic
laboratori
although
impact
remain
unclear
diagnosi
rv
frequent
children
evid
viral
infect
present
pediatr
communityacquir
pneumonia
use
molecular
diagnost
ruuskanen
et
al
routin
diagnosi
respiratori
viru
infect
adult
popul
recent
sinc
respiratori
virus
consid
benign
long
time
respiratori
virus
detect
adult
communityacquir
pneumonia
ruuskanen
et
al
impact
respiratori
viru
diagnosi
specif
pediatr
adult
popul
eg
neonat
patient
cystic
fibrosi
neutropen
patient
patient
chronic
obstruct
pulmonari
diseas
copd
still
incomplet
understood
articl
review
avail
data
highlight
unresolv
question
costeffect
infect
control
clinic
util
public
health
impact
multiplex
respiratori
viru
assay
mani
multiplex
respiratori
viru
assay
publish
market
last
year
differ
nucleic
acid
base
amplif
technolog
use
detect
respiratori
virus
includ
polymeras
chain
reaction
pcr
nucleic
acid
sequencebas
amplif
transcript
mediat
amplif
strand
displac
amplif
loop
mediat
isotherm
amplif
roll
circl
amplif
helicasedepend
amplif
multiplex
ligationdepend
probe
amplif
howev
method
appropri
multiplex
pcr
emerg
easiest
technolog
multiplex
larg
number
target
first
multiplex
respiratori
viru
assay
use
gel
electrophoresi
detect
method
long
labour
intens
necessit
manipul
ethidium
bromid
assay
use
realtim
pcr
design
moder
multiplex
reaction
eg
influenza
influenza
b
influenza
influenza
influenza
b
rsv
parainfluenza
perform
combin
cover
larger
rang
virus
eg
prodess
simplexa
respiratori
pathogen
fasttrack
diagnost
altona
diagnost
strategi
adapt
quantit
result
sampl
collect
appropri
standard
curv
amplifi
reaction
howev
quantit
commerci
assay
avail
yet
limit
multiplex
reaction
target
possibl
theori
get
better
sensit
elimin
primer
dimer
competit
multipl
target
assay
use
highli
multiplex
reaction
includ
target
target
reaction
assay
need
new
detect
method
order
identifi
easili
rapidli
target
present
specimen
detect
technolog
includ
microspher
hybrid
associ
flow
cytomet
detect
led
camera
detect
barcod
detect
eg
xtag
rvp
resplex
ii
multicodeplx
microcapillari
electrophoresi
eg
seeplex
respifind
iceplex
electrospray
ioniz
mass
spectrometri
eg
plexid
nestedpcr
melt
curv
analysi
eg
filmarray
solid
phase
hybrid
microarray
eg
infin
respiratori
viru
panel
ngen
respiratori
viru
analyespecif
reagent
verigen
respiratori
viru
plu
nucleic
acid
test
icub
esensor
genmark
numer
commerci
multiplex
respiratori
viru
assay
us
food
drug
administr
approv
xtag
rvp
rvp
fast
prodess
assay
verigen
respiratori
viru
plu
nucleic
acid
test
filmarray
respiratori
panel
seen
last
year
increas
number
studi
compar
commerci
laboratori
develop
assay
well
studi
compar
commerci
assay
studi
difficult
perform
high
cost
reagent
larg
number
target
valid
best
way
perform
comparison
studi
compar
head
head
two
three
method
prospect
collect
sampl
howev
virus
chang
epidemiolog
difficult
collect
enough
sampl
valid
everi
target
overal
multiplex
respiratori
viru
assay
compar
perform
assay
small
differ
perform
among
differ
target
depend
circul
strain
problem
encount
mainli
lack
sensit
specif
subtyp
adenoviru
inabl
differenti
rhinoviru
enteroviru
bibbi
et
al
chandrasekaran
et
al
gharabaghi
et
al
hayden
et
al
mahoni
et
al
renaud
et
al
princip
differ
among
multiplex
respiratori
viru
assay
concern
throughput
turnaround
time
eas
use
autom
versatil
use
close
system
reduc
contamin
cost
number
analys
perform
expect
turnaround
time
dictat
best
assay
clinic
laboratori
contamin
issu
report
open
platform
need
manipul
amplif
product
ideal
multiplex
respiratori
viru
assay
would
assay
close
system
high
throughput
short
turnaround
time
although
mani
would
consid
quantit
result
use
differenti
shed
symptomat
infect
follow
immunocompromis
patient
antivir
treatment
literatur
inconsist
correl
viral
load
symptom
franz
et
al
jansen
et
al
martin
et
al
import
mention
multiplex
pcr
detect
target
includ
reaction
user
depend
molecular
assay
increas
necess
constant
review
target
essenti
process
alway
easi
use
commerci
platform
publicis
target
mutant
virus
emerg
give
fals
neg
result
molecular
assay
limit
multiplex
pcr
import
consid
high
risk
popul
set
even
though
multiplex
pcr
assay
detect
sever
differ
virus
simultan
rapidli
advantag
term
cost
reduct
rapid
diagnost
assay
dfa
antigen
detect
still
unclear
rapid
antigen
diagnost
test
viral
infect
becam
wide
use
sever
studi
demonstr
clinic
util
reduc
length
hospit
stay
perform
ancillari
diagnost
test
antibiot
consumpt
among
pediatr
bonner
et
al
esposito
et
al
sharma
woo
et
al
abans
et
al
et
al
byington
et
al
ferronato
et
al
iyer
et
al
noyola
demmler
adult
barenfang
et
al
dheilli
et
al
falsey
et
al
popul
costeffect
also
shown
popul
barenfang
et
al
woo
et
al
howev
specif
set
emerg
depart
er
recent
cochran
analysi
show
statist
signific
differ
antibiot
prescript
er
length
stay
young
children
present
acut
febril
respiratori
ill
test
rapid
antigen
viral
diagnost
assay
er
compar
test
doan
et
al
differ
hospit
patient
er
patient
illustr
diagnost
tool
must
use
specif
set
order
provid
benefit
sinc
advent
molecular
diagnosi
differ
author
tri
demonstr
multiplex
pcr
could
costeffect
compar
convent
rapid
diagnost
assay
despit
reduc
turnaround
time
higher
sensit
specif
capac
detect
extend
rang
virus
clinic
financi
gain
afford
pcr
seem
modest
garciagarcia
et
al
show
compar
convent
virolog
diagnosi
use
respiratori
viru
pcr
result
reduct
antibiot
prescript
garciagarcia
et
al
oosterheert
et
al
perform
random
control
trial
evalu
clinic
econom
impact
realtim
pcr
detect
respiratori
virus
atyp
pathogen
among
hospit
adult
despit
notabl
increas
etiolog
diagnost
yield
studi
fail
demonstr
statist
signific
reduct
antibiot
use
addit
diagnost
test
order
antibiot
cost
length
hospit
stay
oosterheert
et
al
similar
result
obtain
wishaupt
et
al
perform
multicent
control
clinic
trial
among
pediatr
patient
netherland
conclud
even
revers
transcriptas
pcr
rtpcr
yield
viral
diagnos
signific
influenc
patient
care
wishaupt
et
al
contrast
mahoni
et
al
gener
cost
analysi
studi
determin
multiplex
pcr
test
less
costli
convent
virolog
assay
use
decis
tree
analyt
model
techniqu
compar
cost
four
diagnost
strategi
cost
calcul
took
account
viral
assay
cost
entir
cost
hospit
stay
adjust
accord
test
outcom
true
fals
posit
neg
result
show
perform
luminex
xtag
rvp
alon
least
costli
approach
mahoni
et
al
pauciti
data
avail
heterogen
assay
studi
difficult
conclud
molecular
diagnosi
costeffect
approach
routin
use
compar
convent
test
howev
probabl
cost
calcul
includ
financi
impact
molecular
assay
hospit
stay
antibiot
use
infect
control
would
favour
studi
need
determin
popul
situat
multiplex
pcr
would
use
order
optim
clinic
financi
impact
strictli
laboratori
point
view
establish
multiplex
pcr
could
effici
costeffect
dunda
et
al
demonstr
laboratori
luminex
xtag
rvp
slightli
expens
convent
techniqu
increas
laboratori
effici
decreas
handson
time
oper
step
moreov
offer
possibl
standard
workflow
respiratori
specimen
attract
strategi
conform
lean
methodolog
dunda
et
al
also
australian
studi
evalu
perform
laboratori
develop
pcr
compar
dfa
viral
cultur
author
conclud
molecular
diagnosi
costeffect
particularli
consid
higher
sensit
rapid
turnaround
time
low
cost
techniqu
patent
syrmi
et
al
summari
molecular
diagnosi
attract
virolog
laboratori
era
increas
demand
decreas
avail
medic
technologist
howev
claim
multiplex
pcr
costeffect
laboratori
evalu
cost
assay
desir
expect
number
specimen
analyz
turnaround
time
desir
abil
batch
specimen
order
reduc
cost
techniqu
use
multiplex
respiratori
viru
assay
high
rate
viral
coinfect
report
rang
depend
differ
popul
younger
children
particularli
attend
daycar
higher
rate
coinfect
mani
studi
perform
differ
set
includ
outpati
inpati
children
upper
respiratori
tract
infect
bronchiol
pneumonia
tri
determin
coinfect
impact
symptom
ill
outcom
studi
shown
fever
longer
hospit
stay
progress
pneumonia
hypoxia
antibiot
use
aberl
et
al
calvo
et
al
esposito
et
al
franz
et
al
paranhosbaccala
et
al
mani
other
shown
differ
sometim
protect
effect
legg
et
al
marguet
et
al
martin
et
al
papenburg
et
al
renoi
et
al
esper
et
al
determin
presenc
protect
effect
copathogen
influenza
includ
rhinoviru
wors
outcom
coinfect
includ
respiratori
virus
esper
et
al
anoth
unresolv
question
respiratori
viral
coinfect
whether
random
two
studi
shown
statist
correl
associ
specif
virus
associ
differ
third
studi
show
associ
brunstein
et
al
peng
et
al
tanner
et
al
multiplex
respiratori
viru
assay
definit
help
elucid
interpret
coinfect
allow
peopl
perform
studi
accumul
data
howev
possibl
interpret
data
necessit
quantit
result
order
realli
discrimin
true
coinfect
asymptomat
shed
avail
rapid
diagnost
assay
essenti
optim
infect
control
team
effort
reduc
transmiss
virul
resist
pathogen
hospit
use
well
illustr
widespread
use
pcr
detect
vancomycin
resist
enterococci
methicillin
resist
staphylococcu
aureu
clostridium
difficil
subsequ
guidanc
infect
control
measur
especi
patient
cohort
seem
evid
intuit
viral
diagnost
assay
precis
multiplex
pcr
could
afford
similar
advantag
rapid
precis
etiolog
diagnosi
could
valuabl
reduc
nosocomi
respiratori
viral
infect
benefit
could
even
substanti
pediatr
unit
mill
et
al
posfaybarb
et
al
zorc
hall
upper
lower
respiratori
tract
infect
frequent
coinfect
two
virus
unusu
patient
less
like
compli
respiratori
etiquett
howev
cohort
measur
still
current
reli
observ
clinic
sign
symptom
instead
object
viral
diagnost
data
although
sever
author
gunson
carman
et
al
templeton
et
al
mention
perform
multiplex
pcr
institut
benefici
infect
control
studi
aim
demonstr
hypothesi
also
even
strategi
immedi
test
cohort
prefer
difficult
challeng
clinic
microbiolog
laboratori
accommod
costeffect
reason
laboratori
often
batch
specimen
consequ
perform
techniqu
twice
day
result
turnaround
time
significantli
longer
one
need
implement
infect
control
measur
time
fashion
recent
outbreak
sever
acut
respiratori
syndrom
includ
sever
acut
respiratori
syndrom
sar
hcov
avian
influenza
pandem
influenza
highlight
necess
effect
respiratori
viru
surveil
human
popul
increas
contact
anim
encount
urban
rapidli
evolv
develop
countri
risk
pandem
signific
mani
public
health
institut
around
world
develop
structur
network
respiratori
viru
surveil
often
includ
sentinel
hospit
report
detect
rate
variou
virus
mani
year
surveil
network
focus
influenza
discoveri
sar
hcov
reinforc
potenti
respiratori
viru
emerg
caus
sever
diseas
even
rhinoviru
associ
sever
outbreak
influenzalik
ill
among
institut
outbreak
longtin
et
al
econom
impact
respiratori
viru
outbreak
model
highlight
anoth
role
respiratori
viru
surveil
achonu
et
al
halasa
et
al
extend
use
multiplex
respiratori
assay
clinic
laboratori
improv
surveil
efficaci
procur
benefit
gener
commun
fox
wong
et
al
major
impact
respiratori
viru
infect
adult
pediatr
patient
hematolog
malign
hematopoiet
stem
cell
transplant
solid
organ
transplant
recogn
last
decad
immunocompromis
popul
respiratori
virus
high
rate
progress
pneumonia
among
patient
mortal
rang
also
possibl
respiratori
viru
infect
unrecogn
benign
symptom
impact
longterm
pulmonari
function
modul
lung
immunolog
defens
adenoviru
infect
transplant
set
potenti
replic
organ
caus
hepat
pneumon
nephriti
coliti
enceph
death
studi
look
specif
virus
would
detect
convent
virolog
ie
rhinoviru
coronaviru
human
metapneumoviru
describ
possibl
complic
associ
virus
number
respiratori
virus
impact
outcom
transplant
consist
increas
screen
multipl
respiratori
virus
consid
best
practic
laboratori
develop
realtim
pcr
assay
multiplex
respiratori
viru
assay
shown
superior
convent
virolog
set
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
kuyper
et
al
lee
et
al
van
elden
et
al
van
kraaij
et
al
weinberg
et
al
kuyper
et
al
show
multiplex
realtim
pcr
two
time
sensit
cultur
four
time
sensit
direct
immunofluoresc
hsct
patient
patient
posit
realtim
pcr
lower
viral
load
studi
look
yet
impact
detect
low
viral
load
transplant
set
potenti
reactiv
respiratori
virus
context
increas
immunosuppress
graft
versu
host
diseas
acut
reject
well
known
hammond
et
al
also
describ
superior
multiplex
respiratori
viru
assay
detect
respiratori
virus
among
hsct
sot
patient
two
time
virus
detect
multiplex
realtim
pcr
assay
idaho
filmarray
rvp
compar
convent
assay
major
virus
detect
convent
virolog
rhinoviru
enteroviru
human
metapneumoviru
coronaviru
hammond
et
al
similar
result
describ
murali
et
al
murali
et
al
use
multicodeplx
respiratori
panel
detect
three
time
virus
patient
hematolog
malign
convent
method
schnell
et
al
schnell
et
al
use
detect
time
viru
immunocompromis
patient
acut
respiratori
failur
direct
immunofluoresc
hayden
et
al
hayden
et
al
compar
multiplex
respiratori
viru
assay
realtim
pcr
immunocompromis
children
filmarray
rvp
resplex
ii
panel
similar
perform
immunocompromis
children
yearsold
filmarray
rvp
better
perform
resplex
older
children
explain
lower
viral
load
shed
older
patient
lower
sensit
resplex
assay
studi
sensit
filmarray
rvp
compar
realtim
pcr
resplex
significantli
less
sensit
realtim
pcr
babadi
et
al
babadi
et
al
compar
filmarray
rvp
xtag
rvp
fast
convent
method
pediatr
cancer
hospit
multiplex
assay
detect
time
virus
convent
method
filmarray
rvp
significantli
higher
sensit
xtag
rvp
fast
even
resolut
discord
result
virus
detect
qualit
multiplex
assay
compar
convent
method
probabl
low
viral
load
shown
quantit
realtim
pcr
analys
kuyper
et
al
kuyper
et
al
howev
interpret
posit
qualit
multiplex
assay
result
difficult
interpret
quantit
result
although
correl
viral
load
symptom
clinic
outcom
perform
studi
need
interpret
signific
high
low
viral
load
milano
et
al
peck
et
al
studi
look
clinic
impact
respiratori
virus
hsct
patient
done
use
laboratorydevelop
realtim
pcr
like
similar
studi
use
commerci
multiplex
assay
would
similar
result
lung
transplant
patient
xtag
rvp
assay
use
evalu
clinic
impact
communityacquir
respiratori
virus
kumar
et
al
kumar
et
al
describ
increas
risk
biopsi
proven
acut
reject
reach
within
month
follow
respiratori
viru
infect
compar
group
without
infect
use
multiplex
assay
larger
scale
help
understand
role
virus
transplant
set
import
note
immunocompromis
patient
influenza
treatabl
rsv
adenoviru
possibl
parainfluenza
human
metapneumoviru
well
studi
suggest
treatment
virus
ribavirin
cidofovir
specif
immunoglobulin
new
drug
come
pipelin
da
may
posit
outcom
immunocompromis
patient
infect
untreat
virus
immunosuppress
reduct
signific
impact
use
antivir
drug
immunocompromis
patient
often
anoth
reason
highlight
necess
rapid
diagnosi
multiplex
assay
turnaround
time
hour
hour
lead
next
day
diagnosi
filmarray
respiratori
viru
panel
advantag
short
turnaround
time
hour
similar
direct
immunofluoresc
increas
sensit
therefor
may
particularli
use
immunocompromis
popul
although
result
qualit
impact
use
expens
multiplex
molecular
assay
immunocompromis
patient
evalu
compar
studi
look
costeffect
morbid
mortal
nevertheless
transplant
center
alreadi
use
multiplex
assay
signific
impact
respiratori
viru
infect
popul
anoth
aspect
costeffect
respiratori
viru
detect
relat
manag
febril
neutropenia
respiratori
virus
frequent
identifi
hematolog
patient
without
hsct
present
febril
neutropenia
hakim
et
al
koskenvuo
et
al
lindblom
et
al
et
al
suryadevara
et
al
torr
et
al
possibl
detect
respiratori
virus
mean
multiplex
assay
would
chang
manag
less
immunocompromis
patient
lead
outpati
manag
reduc
antimicrobi
use
earlier
discharg
shown
torr
et
al
torr
et
al
screen
respiratori
virus
multiplex
assay
asymptomat
pre
posttransplant
patient
anoth
unresolv
question
impact
cost
care
outcom
studi
peck
et
al
peck
et
al
suggest
delay
transplant
better
option
symptomat
rsv
upper
respiratori
tract
infect
present
clear
data
avail
asymptomat
rsv
even
symptomat
benign
virus
rhinoviru
coronaviru
mani
report
highlight
frequenc
respiratori
viru
outbreak
hematolog
transplant
set
detect
respiratori
virus
hsct
patient
prolong
hospit
day
even
week
one
biggest
impact
multiplex
assay
may
manag
immunocompromis
patient
concern
infect
control
practic
higher
sensit
detect
lead
better
isol
practic
less
transmiss
howev
prolong
shed
low
viral
load
asymptomat
patient
mani
patient
requir
long
term
isol
unnecessari
isol
associ
higher
cost
lower
qualiti
life
reduc
qualiti
care
abad
et
al
morgan
et
al
ferguson
et
al
suggest
use
clinic
score
system
screen
appli
infect
control
procedur
ferguson
et
al
clearli
best
infect
control
practic
long
term
asymptomat
shedder
determin
yet
molecular
epidemiolog
might
help
resolv
issu
mani
year
viral
respiratori
tract
infect
recogn
caus
pulmonari
exacerb
decreas
lung
function
among
cystic
fibrosi
cf
patient
armstrong
et
al
collinson
et
al
ramsey
bw
van
ewijk
et
al
wang
et
al
respiratori
virus
also
consid
predispos
factor
secondari
bacteri
infect
collinson
et
al
johansen
hoibi
petersen
et
al
hospit
armstrong
et
al
wang
et
al
advent
molecular
assay
viral
diagnost
test
cf
popul
poor
detect
rate
explain
factor
intrins
cf
specimen
mucoid
natur
bacteri
fungal
overgrowth
inhibit
compromis
viru
recoveri
factor
inher
limit
techniqu
use
poor
sensit
serolog
assay
inabl
recov
noncultiv
newli
identifi
virus
rhinoviru
coronaviru
metapneumoviru
recent
studi
use
multiplex
pcr
evalu
frequenc
clinic
impact
respiratori
viral
ill
cf
patient
result
demonstr
viral
respiratori
tract
infect
frequent
caus
respiratori
ill
cf
popul
involv
acut
exacerb
asner
et
al
burn
et
al
olesen
et
al
wat
et
al
durat
sever
symptom
cf
popul
increas
compar
healthi
control
subject
burn
et
al
van
ewijk
et
al
higher
viral
diagnost
yield
afford
multiplex
pcr
confirm
assay
adequ
reliabl
cf
respiratori
specimen
analysi
asner
et
al
wat
et
al
one
studi
asner
et
al
conclud
viralrel
exacerb
detect
resplex
ii
associ
wors
sever
qualiti
life
score
compar
nonvir
exacerb
asner
et
al
result
suggest
respiratori
virus
serious
consid
differenti
diagnosi
acut
pulmonari
exacerb
cf
subject
consid
sensit
specif
diagnost
assay
avail
antivir
therapi
may
relev
use
circumst
final
confirm
viral
etiolog
may
help
physician
decid
suspend
antibiot
treatment
therebi
minim
antibiot
resist
emerg
critic
prognost
outcom
patient
prematur
infant
without
bronchopulmonari
dysplasia
infant
congenit
heart
diseas
repres
anoth
highrisk
popul
respiratori
viru
infect
abund
literatur
rsv
respiratori
viru
infect
neonat
publish
older
studi
use
convent
virolog
show
rel
low
incid
viral
infect
outpati
neonat
bronchopulmonari
dysplasia
visit
respiratori
worsen
morbid
signific
kinney
et
al
retrospect
studi
year
report
respiratori
viral
infect
neonat
intens
care
unit
nicu
less
infant
verboonmaciolek
et
al
mani
outbreak
variou
respiratori
virus
describ
sever
medic
econom
impact
faden
et
al
gagneur
et
al
halasa
halasa
et
al
sagrera
et
al
recent
studi
prospect
screen
symptomat
asymptomat
prematur
infant
nicu
use
xtag
multiplex
pcr
twice
weekli
respiratori
virus
identifi
prematur
born
infant
birth
hospit
length
hospit
stay
significantli
longer
day
vs
day
bronchopulmonari
dysplasia
frequent
infect
infant
bennett
et
al
studi
uniqu
first
highlight
impact
respiratori
viru
infect
would
suspect
clinician
rais
question
intens
monitor
set
human
rhinoviru
identifi
use
molecular
diagnosi
frequent
caus
hospit
lowbirthweight
infant
initi
discharg
miller
et
al
similarli
commerci
multiplex
pcr
seeplex
ace
detect
use
diagnos
respiratori
infect
infant
congenit
heart
diseas
anoth
major
risk
factor
sever
diseas
comparison
dfa
sensit
multiplex
pcr
better
detect
respiratori
virus
sampl
vs
kanashiro
et
al
util
multiplex
pcr
neonat
infant
congenit
heart
diseas
seem
obviou
data
necessari
explor
impact
popul
screen
nicu
respiratori
virus
identifi
major
caus
copd
exacerb
occur
episod
rhinoviru
frequent
respiratori
viru
detect
hutchinson
et
al
kherad
et
al
mcmanu
et
al
mohan
et
al
rohd
et
al
seemung
et
al
high
rate
viru
detect
acut
exacerb
copd
rais
question
role
antibiot
circumst
rosel
et
al
kherad
et
al
current
guidelin
still
recommend
administr
antibiot
base
clinic
criteria
without
consid
diagnost
assay
respiratori
virus
global
strategi
diagnosi
mapoc
studi
use
procalcitoninbas
guidelin
decreas
use
antibiot
stolz
et
al
kherad
et
al
tri
corrobor
viral
diagnosi
use
biomark
creactiv
protein
procalcitonin
order
strength
viral
diagnosi
rule
bacteri
infect
differ
biomark
level
signific
group
without
viral
infect
kherad
et
al
howev
studi
biomark
level
often
perform
begin
antibiot
treatment
studi
yet
look
clinic
outcom
treat
antibiot
presenc
viru
detect
costeffect
respiratori
viru
assay
popul
varkey
varkey
multiplex
respiratori
viru
assay
use
yet
full
potenti
aid
clinic
manag
mani
laboratori
alreadi
use
differ
purpos
specif
set
use
determin
pediatr
pneumonia
febril
neutropenia
cf
copd
exacerb
exampl
multiplex
respiratori
viru
assay
could
reduc
antibiot
prescript
systemat
patient
screen
immunocompromis
neonat
unit
could
potenti
prevent
outbreak
improv
patient
care
data
cost
effect
respiratori
viru
detect
infect
control
procedur
critic
need
order
use
multiplex
respiratori
viru
assay
appropri
